Effects of chemotherapy and psychosocial distress on perceived cognitive disturbances in Asian breast cancer patients

Annals of Pharmacotherapy

Volumn 46, Issue 12, 2012, Pages 1645-1655

  Cheung, Yin Ting ^a   Shwe, Maung ^a   Chui, Wai Keung ^a   Chay, Wen Yee ^b   Ang, Soo Fan ^b   Dent, Rebecca Alexandra ^b   Yap, Yoon Sim ^b   Lo, Soo Kien ^b   Ng, Raymond Chee Hui ^b   Chan, Alexandre ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Anxiety; Cancer; Chemobrain; Cognitive function; Psycho oncology; Psychosocial distress; Quality of life

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; LETROZOLE; TAMOXIFEN;

ADULT; ANXIETY; ARTICLE; BECK ANXIETY INVENTORY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL ASSESSMENT TOOL; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY COGNITIVE FUNCTION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENTAL STRESS; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SINGAPORE; SOCIAL PSYCHOLOGY;

EID: 84984560482     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R408     Document Type: Article

References (47)

1. Chen ML, Miaskowski C, Liu LN, Chen SC. Changes in perceived attentional function in women following breast cancer surgery. Breast Cancer Res Treat 2012;131:599-606.
2. Tel H, Dogan S. Fatigue, anxiety and depression in cancer patients. Neurology, Psychiatry and Brain Research 2011;17:42-5.
3. Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003;21:4175-83.
4. Reid-Arndt SA, Hsieh C, Perry MC. Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer. Psychooncology 2010;19:535-44.
5. Redeker NS, Lev EL, Ruggiero J. Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Sch Inq Nurs Pract 2000;14:275-90; discussion 91.
6. Nguyen J, Cramarossa G, Bruner D, et al. A literature review of symptom clusters in patients with breast cancer. Expert Rev Pharmacoecon Outcomes Res 2011;11:533-9.
7. Cheung YT, Shwe M, Tan YP, Fan G, Ng R, Chan A. Cognitive changes in multiethnic Asian breast cancer patients: a focus group study. Ann Oncol 2012;23:2547-52.
8. National Comprehensive Cancer Network. NCCN clinical practice guide lines in cancer-related fatigue version 1.2013. www.nccn.org/professionals/physician-gls/pdf/fatigue.pdf (accessed 2012 Nov 30).
9. Hurria A, Somlo G, Ahles T. Renaming "chemobrain". Cancer Invest 2007;25:373-7.
10. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008;19:623-9.
11. Schagen SB, Vardy J. Cognitive dysfunction in people with cancer. Lancet Oncol 2007;8:852-3.
12. Vardy J. Cognitive function in breast cancer survivors. Cancer Treat Res 2009;151:387-419.
13. Pullens MJJ, De Vries J, Roukema JA. Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology 2010;19:1127-38.
14. Moon S, Kim SH, Kim MJ. Perceived cognitive function and related factors in Korean women with breast cancer. Asian Nurs Res 2011;5:141-50.
15. Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle G. Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc 2009;15:951-62.
16. Van Esch L, Roukema JA, Ernst MF, Nieuwenhuijzen GAP, De Vries J. Combined anxiety and depressive symptoms before diagnosis of breast cancer. J Affect Disord 2012;136:895-901.
17. Ahles TA, Saykin AJ, McDonald BC, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008;110:143-52.
18. Wefel JS, Vidrine DJ, Veramonti TL, et al. Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer 2011;117:190-6.
19. Garssen B. Psychological factors and cancer development: evidence after 30 years of research. Clin Psychol Rev 2004;24:315-38.
20. Wagner LI, Sweet J, Butt Z, Lai J-s, Cella D. Measuring patient self-reported cognitive function: development of the Functional Assessment of Cancer Therapy-Cognitive Function instrument. J Support Oncol 2009; 7:W32-9.
21. Bonomi AE, Cella D, Hahn EA, et al. Multilingual translation of the functional assessment of cancer therapy (FACT) quality of life measurement system. Qual Life Res 1996;5:309-20.
22. Eremenco S, Arnold B, Cella D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof 2005;28:212-32.
23. Wild D, Grove A, Martin M, et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005;8:94-104.
24. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
25. Luo N, Fones CSL, Lim SE, Xie F, Thumboo J, Li SC. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): validation of English version in Singapore. Qual Life Res 2005;14:1181-6.
26. Cheung YB, Thumboo J, Goh C, Khoo KS, Che W, Wee J. The equivalence and difference between the English and Chinese versions of two major, cancer-specific, health-related quality-of-life questionnaires. Cancer 2004;101:2874-80.
27. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56:893-7.
28. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-44.
29. Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 2010;28:4434-40.
30. Fan HGM, Houédé-Tchen N, Yi QL, et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1-and 2-year follow-up of a prospective controlled study. J Clin Oncol 2005;23:8025-32.
31. Mehnert A, Scherwath A, Schirmer L, et al. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 2007;66:108-18.
32. Shilling V, Jenkins V, Fallowfield L, Howell T. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol 2003; 86:405-12.
33. Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 2010; 28:1294-300.
34. Jacobsen PB, Garland LL, Booth-Jones M, et al. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage 2004;28:7-18.
35. Joly F, Rigal O, Noal S, Giffard B. Cognitive dysfunction and cancer: which consequences in terms of disease management? Psychooncology 2011;20:1251-8.
36. Schwartz CE, Bode R, Repucci N, Becker J, Sprangers MAG, Fayers PM. The clinical significance of adaptation to changing health: a meta-analysis of response shift. Qual Life Res 2006;15:1533-50.
37. NCCN clinical practice guidelines in cancer-related fatigue version 1. www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf (accessed 2012 Jan 9).
38. Breckenridge LM, Bruns GL, Todd BL, Feuerstein M. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors. Psychooncology 2012;21:43-53.
39. Bender CM, Sereika SM, Brufsky AM, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 2007;14:995-8.
40. Cunningham RS. Anemia in the oncology patient: cognitive function and cancer. Cancer Nurs 2003;26:38S-42S.
41. Jansen C, Miaskowski C, Dodd M, Dowling G, Kramer J. Potential mechanisms for chemotherapy-induced impairments in cognitive function. Oncol Nurs Forum 2005;32:1151-63.
42. Janelsins MC, Mustian KM, Palesh OG, et al. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer 2011;1-9.
43. Myers JS. The possible role of cytokines in chemotherapy-induced cognitive deficits. Adv Exp Med Biol 2010;678:119-23.
44. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodys-plastic syndrome. Cancer 2005;104:788-93.
45. Cheung YT, Lim SR, Chan A. The intermediary role of cytokines in chemotherapy-associated cognitive impairment: a systematic review. Support Care Cancer 2012;20:S130.
46. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008; 8:887-99.
47. Schagen SB, Das E, van Dam FSAM. The influence of priming and preexisting knowledge of chemotherapy-associated cognitive complaints on the reporting of such complaints in breast cancer patients. Psychooncology 2009;18:674-8.